本帖最后由 老马 于 2012-1-13 21:20 编辑
8 U4 ?9 B* O2 @7 v+ @* @+ P! M
# ^6 Y' M( R1 V& g" ^5 A爱必妥和阿瓦斯丁的比较. Z; O$ m( c* Z3 V1 H
+ `0 a& q; P" K. H2 s/ Ahttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/; p% S x4 F3 U ~6 i; U
; P# S: C3 S P9 R5 X& T" C b
. ]: V# p. J9 q7 k0 \2 Q6 whttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/1 a8 g* J1 m, b4 l( |
==================================================0 \! _$ |- b) C# B/ |
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)( Z/ u U; }. ?0 {, w6 f5 I
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
: B! F+ i/ i0 j' }Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.! ~7 {& J) h' q
|
显身卡
# ]/ \, Q$ r4 X1 k+ F* B% A" Z( J$ `
